Scientists say they have built a cell from scratch for the first time that feeds, grows and replicates like a natural cell, a breakthrough in synthetic biology.
CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for relapsed or refractory B-cell non-Hodgkin lymphomas. Long-term results and curative potential remain uncertain. We ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results